Jeong Gyun Oh Net Worth

Jeong Gyun Oh biography

Jeong Gyun Oh serves as Independent Director of the Company. Prior to that, he had served on the Board of Private NeuroBo since March 2019. From January 2017 until February 2019, Mr. Oh served as Chief Financial Officer of JK BioPharma Solutions, Inc., a privately-held, drug development company focused on early stage developmental assets, and has served as the President and Chief Executive Officer of JK BioPharma Solutions, Inc. since March 2019. From August 2001 until December 2016, Mr. Oh held multiple financial positions ultimately culminating in his service as Vice President of Finance with CDNetworks Co., Ltd., a global content delivery network service company. Mr. Oh holds a B.A. in business administration from Seoul National University. Our Board believes that Mr. Oh's experience as a corporate finance executive with extensive expertise in financial operations, including financial/managerial accounting, business planning and budgeting qualify him to serve as a director.

How old is Jeong Oh?

Jeong Oh is 46, he's been the Independent Director of NeuroBo Pharmaceuticals Inc since 2019. There are 9 older and 2 younger executives at NeuroBo Pharmaceuticals Inc. The oldest executive at NeuroBo Pharmaceuticals Inc is Michael Salsbury, 70, who is the Independent Director.

What's Jeong Oh's mailing address?

Jeong's mailing address filed with the SEC is C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON, MA, 02115.

Insiders trading at NeuroBo Pharmaceuticals Inc

Over the last 5 years, insiders at NeuroBo Pharmaceuticals Inc have traded over 0$ worth of NeuroBo Pharmaceuticals Inc stock and bought 2,544,530 units worth 7,964,379$ . The most active insiders traders include St Co., Ltd Dong A、Tae Heum Jeong、Steven R. Ph.D. Gullans. On average, NeuroBo Pharmaceuticals Inc executives and independent directors trade stock every 0 days with the average trade being worth of 9,541,988$. The most recent stock trade was executed by St Co., Ltd Dong A on 23 June 2024, trading 2,544,530 units of NRBO stock currently worth 7,964,379$.

What does NeuroBo Pharmaceuticals Inc do?

neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.

NeuroBo Pharmaceuticals Inc executives and stock owners

NeuroBo Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Dr. Ben Gil Price M.D.,
  CEO & Pres
• Nicola Shannon,
  Vice President - Clinical Operations
• Akash Bakshi,
  Sr. VP & COO
• Michael Miller,
  Investor Relations
• Douglas Swirsky,
  Independent Director
• Michael Salsbury,
  Independent Director
• Jeong Gyun Oh,
  Independent Director
• Tae Heum Jeong,
  Independent Director
• Jason Groves,
  Independent Director
• Mark Versavel,
  Chief Medical Officer
• jeong Gu Kang,
  President, Chief Executive Officer, Interim Chief Financial Officer, Secretary, Treasurer and Director
• Na Yeon Kim,
  Independent Chairman of the Board
• Frank Kondrad,
  VP of Corp. & Bus. Devel.
• Dr. Matthew Bardin BCPS, Pharm.D.,
  Sr. VP of Operations
• Dr. Nadja Mannowetz Ph.D.,
  Sr. VP
• Dr. Andrew Bartynski Ph.D.,
  Sr. VP
• Dr. Gil Price M.D.,
  CEO, Pres & Chief Medical Officer
• Dr. Jeong Gu Kang Ph.D.,
  Pres, CEO, Sec., Interim CFO, Treasurer & Director
• St Co., Ltd Dong A,
  
• Mark A Glickman,
  Director
• Akash Bakshi,
  SVP and COO
• Steven R. Ph.D. Gullans,
  Director
• James Patrick Tursi,
  Director
• Ben Gil Price,
  CEO and President
• D Gordon Strickland,
  Director
• Richard Kang,
  Director
• Inc.E&Healthcare Investment...,
  
• Hyung Heon Kim,
  CEO & President
• Marshall H Woodworth,
  Chief Financial Officer